Rakshit Drugs Revenue and Competitors
Estimated Revenue & Valuation
- Rakshit Drugs's estimated annual revenue is currently $9M per year.
- Rakshit Drugs's estimated revenue per employee is $100,500
Employee Data
- Rakshit Drugs has 90 Employees.
- Rakshit Drugs grew their employee count by 32% last year.
Rakshit Drugs Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $56.6M | 563 | 21% | N/A | N/A |
#2 | $15.6M | 155 | 28% | N/A | N/A |
#3 | $19M | 189 | -8% | N/A | N/A |
#4 | $11.2M | 111 | 9% | N/A | N/A |
#5 | $19.6M | 195 | 10% | N/A | N/A |
#6 | $20.3M | 202 | 13% | N/A | N/A |
#7 | $5.3M | 53 | 6% | N/A | N/A |
#8 | $17.3M | 172 | -1% | N/A | N/A |
#9 | $16.1M | 160 | 20% | N/A | N/A |
#10 | $11.7M | 116 | 6% | N/A | N/A |
What Is Rakshit Drugs?
Rakshit Drugs Pvt. Ltd. is a pharmaceuticals company based out of Rakshit House,425/3RT, D.No. 7-1-621/328, S.R. Nagar, Hyderabad, India.
keywords:N/AN/A
Total Funding
90
Number of Employees
$9M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Rakshit Drugs News
2022-04-20 - Amlodipine Besilate Market Size, Share, Growth 2022-2030| Key ...
VPL Chemicals; Rakshit Drugs; Moehs; Dr. Reddy's; Cadila Pharmaceuticals; Amsal Chem; Changzhou Yabang Pharmaceutical; Cipla; Tapi Teva; Suan.
2022-04-06 - Ukrainian officials begin urging evacuations amid reports of new ...
Sami Rakshit, director of Finnish Customs' Enforcement Department, ... decontamination equipment and drugs that could boost its defenses in...
2022-04-06 - 20,488 ghost companies detected in Hyderabad, 3rd-highest in India
Vizag GST Commissionerate booked a case against Hyderabad-based Rakshit drugs private limited, Virupaksha Organics Limited,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $12.2M | 90 | 32% | N/A |
#2 | $14.9M | 90 | 48% | N/A |
#3 | $13.5M | 90 | 20% | N/A |
#4 | $11.6M | 91 | 6% | N/A |
#5 | N/A | 91 | 49% | N/A |